LOBBYIST

Paul Edattel

← Back to lobbyists

200ACTIVITIES
11ORGS REPRESENTED
8BILLS

Revolving door — covered positions

Federal positions Paul held before / during the 2-year LDA window. This is the credibility signal — who they were inside the building before they started lobbying it.

Chief Health Counsel, House Energy & Commerce Committee
Policy Assistant, Office of the Speaker
Professional Staff Member for the Majority at the House Energy & Commerce Committee
Legislative Assistant & Legislative Director, Rep. John Shadegg

Bills they file on

8
S. 86415 mentions
H.R. 16728 mentions
H.R. 9468 mentions
H.R. 52694 mentions
H.R. 14064 mentions
S. 10402 mentions
S. 10412 mentions
H.R. 22142 mentions

Topics in Filings

73

Policy topics Paul files on across all their LD-2 activities.

Medicare and Medicaid Issues×22
HELP Copays Act×15
Physician Payment Reform×14
Copyright issues×12
Intellectual property protection×12
Prescription Drug Pricing Policy×12
Part D changes×11
Prescription drug payment reform. 340B issues×11
General Medicare and Medicaid Issues×11
Drug Pricing and Access×11
Pharmaceutical Supply Chain×11
Pharmacy Benefit Managers×11
Show all 73 topics (+61 more) ▾
Medicare/Medicaid payment reform×10
Supply Chain Issues×10
Alzheimer's Disease×10
Medicare Contractor Reform×9
Maintaining Investments in New Innovation Act×8
ORPHAN Cures Act×8
General telecommunications issues×6
Biosimilars reimbursement issues×6
Pharmacy Benefit Manager Reform×6
Anti Obesity Medication×6
Medicare/Medicaid Coverage and Reimbursement×6
PDUFA. 340B Program×6
Kidney transplantation policy×5
Medicare coverage and reimbursement for diagnostics×5
FDA LDT Regulation×5
Prior Authorization for Medicare Advantage×5
Prescription drug pricing, including MDRP×4
Substance Use Disorder Policy×4
Medicaid drug rebate program×4
Medicare Physician Fee Schedule Provider Reimbursement×4
PAMA AUC×4
Value of imaging×4
General Education on Apollo Global Management×4
Insurance regulation×4
Prescription drug pricing×4
Prostate cancer screening×4
Women's health×4
340B Program×4
Home Infusion for Part B Products×4
Medicare Reimbursement for New Technologies×4
Pediatric Priority Review Voucher Program×4
General issues×4
Diagnostics for patients with rare disease×4
Multi-Cancer Early Detection×4
Drug pricing×4
Medicare reimbursement for diagnostics×4
Lab test regulatory and reimbursement reform×4
Medicare Reimbursement for Prescription Drugs×4
Screening and Diagnosis×4
PET scan coverage and reimbursement and dementia care. 340B Program×4
PPRV×4
General education on kidney care×4
General education about Calyxo×4
Medicare coverage of molecular testing for solid organ allograft rejection×4
Medicare payment of clinical laboratory tests×4
Prior authorization of molecular tests×4
General education on Compass Pharmaceuticals×4
Mental health and PTSD×4
Education around innovative testing for early detection of lung cancer and draft×4
Lung Cancer Screening and Prevention Act×4
Oncology/Artificial Intelligence×4
Hepatitis C Funding×4
Drug pricing and Medicare, including implementation×2
Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients×2
Drug Competition Enhancement Act×2
Affordable Prescriptions for Patients Act×2
Vaccine Policy×2
Coverage and Access and the Vaccine Injury Compensation Fund×2
DRUG Act×2
International Supply Chain×2
March-in rights×1

Issue mix

LDA general-issue codes weighted by activity count.

Health Issues75
Medicare/Medicaid70
Pharmacy17
Copyright/Patent/Trademark12
Taxation/Internal Revenue Code8
Telecommunications6
Economics/Economic Development4
Financial Institutions/Investments/Securities4
Tariff (miscellaneous tariff bills)2
Trade (domestic/foreign)2